Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Natural killer group 2D ligands (NKG2DLs), including MHC class I polypeptide-related sequence A and B (MICA/MICB) and UL16-binding proteins 1 to 3 (ULBP1-3), are stress-induced cell-surface glycoproteins. Under normal physiological conditions, these ligands are minimally expressed or absent on healthy tissues. However, they become significantly upregulated on the surface of cells undergoing cellular stress, viral infection, or malignant transformation. When expressed on tumor cells, they engage the activating immunoreceptor NKG2D on natural killer (NK) cells, CD8+ T cells, and gamma-delta T cells, triggering cytotoxic immune responses and cytokine production to eliminate the abnormal cells.
To evade this immune surveillance, tumor cells frequently employ sheddases (such as ADAM10 and ADAM17 metalloproteinases) to proteolytically cleave MICA/MICB and ULBPs from their cell surface. This shedding process releases soluble ligands (sNKG2DLs) into the circulation, which act as decoys, downregulate NKG2D receptor expression on effector cells, and suppress anti-tumor immunity. Therapeutic strategies targeting these stress ligands include monoclonal antibodies (e.g., CLN-619) that bind to MICA/MICB to prevent their proteolytic shedding and promote antibody-dependent cellular cytotoxicity (ADCC). Additionally, chimeric antigen receptor (CAR) T-cell and NK-cell therapies (such as CYAD-01, CYAD-02, and NKX101) utilize the extracellular domain of NKG2D to target and eliminate tumor cells expressing these stress ligands.
Inhibition of MICA/MICB proteolytic shedding, promotion of antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), and chimeric antigen receptor (CAR) T-cell or NK-cell activation leading to tumor cell lysis.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural killer group 2D ligands (NKG2DL).